Teriparatide: A New Drug for Osteoporosis

[Guest guest]

Teriparatide: A New Drug for Osteoporosis

(July 22, 2002) (Updated December 14, 2002)

S. Bockman, MD, PhD

Head of the Endocrine Service, Hospital for Special Services

Professor of Medicine, Weill College of Medicine of Cornell University

Teriparatide (pronounced teh-rih-PAH-ruh-teyed) is a synthetic version

of human parathyroid hormone. It was recently approved by the U.S. FDA

for the treatment of osteoporosis and will soon be commercially

available from Eli Lilly and Company under the brand name Fortéo.

Teriparatide is a breakthrough in osteoporosis therapy because it is the

first drug that builds bone rather than just slowing bone loss. The

Hospital for Special Surgery has participated in key clinical trials of

the drug and I have been a consultant to Lilly in that context. So we

have a good sense of its usefulness and patient responses.

For the rest of the article, please see:

http://rheumatology.hss.edu/pat/specialreports/teri_pat.asp

I'll tell you where to go!

Mayo Clinic in Rochester

http://www.mayoclinic.org/rochester

s Hopkins Medicine

http://www.hopkinsmedicine.org